{"id":407263,"date":"2021-01-04T07:03:31","date_gmt":"2021-01-04T12:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407263"},"modified":"2021-01-04T07:03:31","modified_gmt":"2021-01-04T12:03:31","slug":"azurrx-biopharma-announces-8-0-million-offerings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/","title":{"rendered":"AzurRx BioPharma Announces $8.0 Million Offerings"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DELRAY BEACH, Fla., Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc. (NASDAQ: AZRX), (\u201cAzurRx\u201d or the \u201cCompany\u201d), a company specializing in the development of non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases, today announced that in conjunction with entering into an exclusive worldwide licensing agreement with First Wave Bio, Inc. (\u201cFirst Wave\u201d) it has entered into a securities purchase agreement (the \u201cPurchase Agreement\u201d) with a single healthcare-focused institutional investor, pursuant to which the Company agreed to sell approximately $8.0 million of Series C 9.00% Convertible Junior Preferred Stock (the \u201cSeries C Preferred Stock\u201d) in a registered direct offering and concurrent private placement. The Company will also issue to the investor unregistered warrants (the \u201cWarrants\u201d) to purchase up to an aggregate of 10,666,668 shares of common stock. The combined purchase price for one share of Series C Preferred Stock and a Warrant is $750.00. The Series C Preferred Stock will have an initial stated value of $750.00 per share and conversion price of $0.75 per share, and will initially be convertible into an aggregate of up to 10,666,668 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof). The Warrants will have an exercise price of $0.80 per share and an expiration term of five and one-half years from the date of issuance. One-half of the shares of Series C Preferred Stock, together with the underlying common stock (or prefunded warrants, as applicable), are being sold in the registered direct offering, and one-half of the shares of Series C Preferred Stock and all of the Warrants, together with the underlying common stock (or prefunded warrants, as applicable), are being sold in the private placement.<\/p>\n<p align=\"justify\">H.C. Wainwright &amp; Co. is acting as exclusive placement agent for the offering.<\/p>\n<p align=\"justify\">AzurRx intends to use the net proceeds received from the offering to fund the upfront cash payment to First Wave in connection with the exclusive worldwide licensing agreement and for other general corporate purposes.<\/p>\n<p align=\"justify\">The registered direct offering and concurrent private placement are expected to close on or about January 5, 2021, subject to the satisfaction of customary closing conditions. The issuance of the shares of common stock underlying the Series C Preferred Stock in excess of certain thresholds, and underlying the Warrants sold in the private placement, is subject to stockholder approval (i) of an amendment to AzurRx\u2019s certificate of incorporation to increase its authorized shares of common stock above 150,000,000 and (i) to satisfy Nasdaq requirements with respect to the issuance of such shares of common stock.<\/p>\n<p align=\"justify\">The Series C Preferred Stock sold in the registered direct offering and underlying shares of common stock (or pre-funded warrants, as applicable) are being offered and sold in the registered direct offering by AzurRx pursuant to a \u201cshelf\u201d registration statement on Form S-3 (File No. 333-231954) including a base prospectus, previously filed with and declared effective by the\u00a0Securities and Exchange Commission (the \u201cSEC\u201d) on June 21, 2019. The registered direct offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the\u00a0SEC\u00a0and will be available on the\u00a0SEC\u2019s\u00a0website located at http:\/\/www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from H.C. Wainwright &amp; Co., 430 Park Avenue, New York, NY 10022 or via telephone at (646) 975-6996 or email placements@hcwco.com.<\/p>\n<p align=\"justify\">The Series C Preferred Stock and Warrants sold in the private placement and underlying shares of common stock (or prefunded warrants, as applicable) are being offered pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the \u201cAct\u201d), and have not been registered under the Act, or applicable state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.<\/p>\n<p align=\"justify\">\n        <strong>About AzurRx BioPharma, Inc.<\/strong><br \/>\n        <br \/>AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a biopharmaceutical company\u00a0specialized\u00a0in the research and development of non-systemic biologics for\u00a0gastrointestinal disorders. The Company is focused on the development of its lead drug\u00a0candidate, MS1819. AzurRx is currently conducting two Phase 2\u00a0clinical trials\u00a0of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial,\u00a0consisting\u00a0of MS1819 in conjunction with porcine-derived\u00a0pancreatic enzyme replacement therapy, the current standard of care. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at\u00a0www.azurrx.com.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company\u2019s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company\u2019s control. Forward-looking statements include those relating to the offering of the Company\u2019s securities, including as to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering, which may be affected by, among others, delays in satisfying or failure to satisfy closing conditions for the registered direct offering and concurrent private placement and adverse changes in general economic and market conditions. It is possible that the Company\u2019s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company\u2019s financial results, including those related to the clinical development of its clinical assets, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company\u2019s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading\u00a0\u201cRisk Factors,\u201d\u00a0as well as the Company\u2019s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.<\/em>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>For more information:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>AzurRx BioPharma, Inc.<br \/>1615 South Congress Avenue<br \/>Suite 103<br \/>Delray Beach, Florida 33445<br \/>Phone: (646) 699-7855<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MnbG1IIqhKF_LiewcIVB3cCcipgEJ3e7YoxC8Gtp7a3HnIDfoXT6colg78GkyB9KphKeHU80lcDyClII16XJJg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@azurrx.com<\/a><\/p>\n<p>\n        <strong>Investor Relations contact:<\/strong>\n      <\/p>\n<p>LifeSci Advisors, LLC.\u00a0<br \/>Hans Vitzthum, Managing Director\u00a0<br \/>1 International Place, Suite 1480\u00a0<br \/>Boston, MA 02110\u00a0<br \/>Phone: (617) 430-7578\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mQVo4_fVdJtcf3fxK480SXE4j3dt_gZTpRD1ibAsUOnCpvK0f5JMslAiV3hDlZYrewqgDy-OD_7yyFh_eFCep2NleFNxjq4RFSDNepc6efc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">hans@lifesciadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3c3e932d-1084-46f5-8e47-1289d6e207ca\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc. (NASDAQ: AZRX), (\u201cAzurRx\u201d or the \u201cCompany\u201d), a company specializing in the development of non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases, today announced that in conjunction with entering into an exclusive worldwide licensing agreement with First Wave Bio, Inc. (\u201cFirst Wave\u201d) it has entered into a securities purchase agreement (the \u201cPurchase Agreement\u201d) with a single healthcare-focused institutional investor, pursuant to which the Company agreed to sell approximately $8.0 million of Series C 9.00% Convertible Junior Preferred Stock (the \u201cSeries C Preferred Stock\u201d) in a registered direct offering and concurrent private placement. The Company will also issue to the investor unregistered warrants (the \u201cWarrants\u201d) to purchase up to an aggregate of 10,666,668 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AzurRx BioPharma Announces $8.0 Million Offerings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407263","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc. (NASDAQ: AZRX), (\u201cAzurRx\u201d or the \u201cCompany\u201d), a company specializing in the development of non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases, today announced that in conjunction with entering into an exclusive worldwide licensing agreement with First Wave Bio, Inc. (\u201cFirst Wave\u201d) it has entered into a securities purchase agreement (the \u201cPurchase Agreement\u201d) with a single healthcare-focused institutional investor, pursuant to which the Company agreed to sell approximately $8.0 million of Series C 9.00% Convertible Junior Preferred Stock (the \u201cSeries C Preferred Stock\u201d) in a registered direct offering and concurrent private placement. The Company will also issue to the investor unregistered warrants (the \u201cWarrants\u201d) to purchase up to an aggregate of 10,666,668 &hellip; Continue reading &quot;AzurRx BioPharma Announces $8.0 Million Offerings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AzurRx BioPharma Announces $8.0 Million Offerings\",\"datePublished\":\"2021-01-04T12:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/\"},\"wordCount\":1142,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/\",\"name\":\"AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\",\"datePublished\":\"2021-01-04T12:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-announces-8-0-million-offerings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AzurRx BioPharma Announces $8.0 Million Offerings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/","og_locale":"en_US","og_type":"article","og_title":"AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk","og_description":"DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc. (NASDAQ: AZRX), (\u201cAzurRx\u201d or the \u201cCompany\u201d), a company specializing in the development of non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases, today announced that in conjunction with entering into an exclusive worldwide licensing agreement with First Wave Bio, Inc. (\u201cFirst Wave\u201d) it has entered into a securities purchase agreement (the \u201cPurchase Agreement\u201d) with a single healthcare-focused institutional investor, pursuant to which the Company agreed to sell approximately $8.0 million of Series C 9.00% Convertible Junior Preferred Stock (the \u201cSeries C Preferred Stock\u201d) in a registered direct offering and concurrent private placement. The Company will also issue to the investor unregistered warrants (the \u201cWarrants\u201d) to purchase up to an aggregate of 10,666,668 &hellip; Continue reading \"AzurRx BioPharma Announces $8.0 Million Offerings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:03:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AzurRx BioPharma Announces $8.0 Million Offerings","datePublished":"2021-01-04T12:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/"},"wordCount":1142,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/","name":"AzurRx BioPharma Announces $8.0 Million Offerings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=","datePublished":"2021-01-04T12:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTcwMyMzOTAyMzYxIzIwODIyMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-announces-8-0-million-offerings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AzurRx BioPharma Announces $8.0 Million Offerings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407263"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407263\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}